

MYELOID TRIALS OPEN TO RECRUITMENT

Disease	Front line or relapsed/refractory	Key entry criteria	Trial name & treatment
CML&AML&MPN	Front line	Patients unfit for standard induction chemotherapy	PRIMULA= Azacitidine with pracinostat or placebo (blinded)
		Older (>60) patients with AML or high risk MDS	AML 18= 1 st cycle DA. Other cycles as per trial design dependent on response to cycle 1
		Older (>60) patients with AML or high risk MDS who are not suitable for intensive chemo	LI-1= Low dose Ara-C in combo with AC220 (quizartinib) or tosedostat or KPT330 (selinexor) or Lenalidomide
		Adults (19-65) with newly diagnosed with ALL	UKALL 14= pre B-cell patient have standard phase 1 therapy alone or with rituximab. T-cell patient standard phase 2 therapy alone or with nelarabine
		Patients with CML who haven't reached deep molecular response (MR4) within 24 months of treatment on imatinib	ASC4MORE= Asciminib added to imatinib versus continued imatinib versus switch to nilotinib
		Patients with AML or MDS with an IDH1 mutation	Forma= FT-2102 as single agent or in combo with azacitidine or cytarabine
CML&AML&MPN	Relapsed/ Refractory	Patients with MDS post failure of hypomethylating agent	Inspire= Rigosertib vs physician's choice
		CD33 positive	B1761031= Mylotarg
	Observational	Adult ≥ 16 years old. ≥10% blasts in blood or marrow with or without dysplastic changes(MPN-AP)at baseline. ≥20% blasts in blood or bone marrow(MPN-BP)at baseline. Patients who are entered into studies with more aggressive therapy as well as those receiving palliation.	Phazar= Quality of life questionnaire 3 monthly